Page 1 | Search Results | Diabetes | American Diabetes Association

1-18 of 18

Sort by

Sort Order Select

Meeting Abstracts

81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology

CYRIELLE CAUSSY, BRUNO VERGÈS, DAMIEN LELEU, LAURENCE DUVILLARD, AMNA ABICHOU-KLICH, BERENICE SEGRESTIN, SYLVIE BIN, ALEXIA ROULAND, DOMINIQUE DELAUNAY, SAMY HADJADJ, CLAIRE PRIMOT, JEAN-MICHEL PETIT, SYBIL CHARRIÈRE, PHILIPPE MOULIN, MASSIMO LEVRERO, BERTRAND CARIOU, EMMANUEL DISSE

Diabetes 2024;73(Supplement_1):81-OR

https://doi.org/10.2337/db24-81-OR

Published: 14 June 2024

View articletitled, 81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology

Meeting Abstracts

1223-P: Frequency and Predictors of Level 2 Time Above Range (TAR) in Older Adults with Type 2 Diabetes on Insulin Therapy—Data from the HYPOAGE Prospective Study

BERTRAND CARIOU, SAMY HADJADJ, ANNE SOPHIE BOUREAU, HYPOAGE STUDY GROUP

Diabetes 2023;72(Supplement_1):1223-P

https://doi.org/10.2337/db23-1223-P

Published: 20 June 2023

View articletitled, 1223-P: Frequency and Predictors of Level 2 Time Above Range (TAR) in Older Adults with Type 2 Diabetes on Insulin Therapy—Data from the HYPOAGE Prospective Study

Meeting Abstracts

1624-P: Hudev-PRE, a Combination of Plant Extracts, Improves Glucose Homeostasis in Both High-Fat Diet C57Bl/6J and Ob/Ob Mice

CEDRIC LE MAY, JEAN-LOUIS BLUA, BERTRAND CARIOU

Diabetes 2023;72(Supplement_1):1624-P

https://doi.org/10.2337/db23-1624-P

Published: 20 June 2023

View articletitled, 1624-P: Hudev-PRE, a Combination of Plant Extracts, Improves Glucose Homeostasis in Both High-Fat Diet C57Bl/6J and Ob/Ob Mice

Meeting Abstracts

1017-P: Association between Death at Day 28 and Components of Microvascular Disease of with Diabetes Hospitalized for Coronavirus Disease-2019 (COVID-19): The CORONADO Study

PIERRE-JEAN SAULNIER, SAMY HADJADJ, LAURENCE KESSLER, MICHEL MARRE, JEAN MICHEL HALIMI, MATTHIEU WARGNY, PIERRE GOURDY, BERTRAND CARIOU, GROUP FOR THE CORONADO STUDY

Diabetes 2021;70(Supplement_1):1017-P

https://doi.org/10.2337/db21-1017-P

Published: 01 June 2021

View articletitled, 1017-P: Association between Death at Day 28 and Components of Microvascular Disease of with Diabetes Hospitalized for Coronavirus Disease-2019 (COVID-19): The CORONADO Study

Meeting Abstracts

670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial

JULIO ROSENSTOCK, BERTRAND CARIOU, ERIK CHRISTIANSEN, CHRISTIN L. HERTZ, EDUARD MONTANYA, MORTEN ABILDLUND NIELSEN, FILIP K. KNOP

Diabetes 2021;70(Supplement_1):670-P

https://doi.org/10.2337/db21-670-P

Published: 01 June 2021

View articletitled, 670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial

Meeting Abstracts

932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program

VANITA R. ARODA, ROBERT BAUER, CHRISTIN L. HERTZ, EDUARD MONTANYA, RASMUS SØRRIG, MARK L. WARREN, BERTRAND CARIOU

Diabetes 2020;69(Supplement_1):932-P

https://doi.org/10.2337/db20-932-P

Published: 01 June 2020

View articletitled, 932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program

Meeting Abstracts

1103-P: Balancing the Risk of DKA and Severe Hypoglycemia with Sotagliflozin in Adults with Type 1 Diabetes

JEREMY PETTUS, BERTRAND CARIOU, SANGEETA SAWHNEY, PHILLIP L. BANKS, MICHAEL J. DAVIES, PABLO LAPUERTA

Diabetes 2020;69(Supplement_1):1103-P

https://doi.org/10.2337/db20-1103-P

Published: 01 June 2020

View articletitled, 1103-P: Balancing the Risk of DKA and Severe Hypoglycemia with Sotagliflozin in Adults with Type 1 Diabetes

Meeting Abstracts

175-OR: Effect of Alirocumab in Individuals with Type 2 Diabetes and High Triglycerides and Low High-Density Lipoprotein Cholesterol

HELEN M. COLHOUN, LAWRENCE A. LEITER, DIRK MÜLLER-WIELAND, BERTRAND CARIOU, KAUSIK K. RAY, FRANCISCO TINAHONES, CATHERINE DOMENGER, ALEXIA LETIERCE, MARC ISRAEL, STEFANO DEL PRATO

Diabetes 2019;68(Supplement_1):175-OR

https://doi.org/10.2337/db19-175-OR

Published: 01 June 2019

View articletitled, 175-OR: Effect of Alirocumab in Individuals with Type 2 Diabetes and High Triglycerides and Low High-Density Lipoprotein Cholesterol

Meeting Abstracts

985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8

BERNARD ZINMAN, VANITA R. ARODA, JOHN B. BUSE, BERTRAND CARIOU, STEWART B. HARRIS, SOREN T. HOFF, KAREN BOJE PEDERSEN, MADS JEPPE TARP-JOHANSEN, EIICHI ARAKI, FOR THE PIONEER 8 INVESTIGATORS

Diabetes 2019;68(Supplement_1):985-P

https://doi.org/10.2337/db19-985-P

Published: 01 June 2019

View articletitled, 985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8

Meeting Abstracts

1212-P: Sotagliflozin Reduces Markers of Arterial Stiffness in T1D: Pooled Analysis from inTandem 1 and inTandem 2 Clinical Trials

HELENA W. RODBARD, ANDREA GIACCARI, MICHAEL J. DAVIES, SANGEETA SAWHNEY, STELLA WANG, SATISH K. GARG, BERTRAND CARIOU

Diabetes 2019;68(Supplement_1):1212-P

https://doi.org/10.2337/db19-1212-P

Published: 01 June 2019

View articletitled, 1212-P: Sotagliflozin Reduces Markers of Arterial Stiffness in T1D: Pooled Analysis from inTandem 1 and inTandem 2 Clinical Trials

Meeting Abstracts

1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA_1c Level at 52 Weeks in Adults with T1D

THOMAS DANNE, JEREMY PETTUS, ANDREA GIACCARI, BERTRAND CARIOU, HELENA W. RODBARD, STUART A. WEINZIMER, MIREILLE BONNEMAIRE, SANGEETA SAWHNEY, STELLA WANG, RITA CASTRO, SATISH K. GARG

Diabetes 2019;68(Supplement_1):1220-P

https://doi.org/10.2337/db19-1220-P

Published: 01 June 2019

View articletitled, 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D

Meeting Abstracts

279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients

BART STAELS, VLAD RATZIU, SVEN FRANCQUE, STEPHEN A. HARRISON, PIERRE BEDOSSA, ALICE ROUDOT, ZOUHER MAJD, JOHN BROZEK, FOUAD BEN-SUDRIK, PASCAL BIRMAN, DEAN W. HUM, SUNEIL HOSMANE, PIERRE CHAUMAT, RéMY HANF, BERTRAND CARIOU, ARUN SANYAL

Diabetes 2019;68(Supplement_1):279-LB

https://doi.org/10.2337/db19-279-LB

Published: 01 June 2019

View articletitled, 279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients

Meeting Abstracts

278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis

BART STAELS, VLAD RATZIU, ARUN J. SANYAL, SVEN FRANCQUE, STEPHEN A. HARRISON, ALICE ROUDOT, JOHN BROZEK, YACINE HAJJI, SOPHIE MEGNIEN, DEAN W. HUM, PASCAL BIRMAN, RéMY HANF, BERTRAND CARIOU

Diabetes 2019;68(Supplement_1):278-LB

https://doi.org/10.2337/db19-278-LB

Published: 01 June 2019

View articletitled, 278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis

Meeting Abstracts

Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2)

THOMAS DANNE, BERTRAND CARIOU, JOHN B. BUSE, SATISH K. GARG, JULIO ROSENSTOCK, PHILLIP L. BANKS, JAKE A. KUSHNER, DARREN K. MCGUIRE, ANNE L. PETERS, SANGEETA SAWHNEY, PAUL STRUMPH

Diabetes 2018;67(Supplement_1):1179-P

https://doi.org/10.2337/db18-1179-P

Published: 01 July 2018

View articletitled, Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2)

Meeting Abstracts

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study)

THOMAS DANNE, BERTRAND CARIOU, PHILLIP L. BANKS, MICHAEL BRANDLE, HELMUT BRATH, EDWARD FRANEK, JAKE A. KUSHNER, PABLO LAPUERTA, DARREN K. MCGUIRE, ANNE L. PETERS, SANGEETA SAWHNEY, PAUL STRUMPH

Diabetes 2018;67(Supplement_1):1122-P

https://doi.org/10.2337/db18-1122-P

Published: 01 July 2018

View articletitled, Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study)

Journal Articles

The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

Michael Joubert, Benoît Jagu, David Montaigne, Xavier Marechal, Angela Tesse, Audrey Ayer, Lucile Dollet, Cédric Le May, Gilles Toumaniantz, Alain Manrique, Flavien Charpentier, Bart Staels, Jocelyne Magré, Bertrand Cariou, Xavier Prieur

Diabetes 2017;66(4):1030–1040

https://doi.org/10.2337/db16-0733

Published: 04 January 2017

View articletitled, The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

Includes: Supplementary data

Journal Articles

FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency

Lucile Dollet, Clara Levrel, Tamer Coskun, Soazig Le Lay, Cedric Le May, Audrey Ayer, Quentin Venara, Andrew C. Adams, Ruth E. Gimeno, Jocelyne Magré, Bertrand Cariou, Xavier Prieur

Diabetes 2016;65(11):3410–3417

https://doi.org/10.2337/db16-0327

Published: 23 August 2016

View articletitled, FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency

Includes: Supplementary data

Journal Articles

Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity

Janne Prawitt, Mouaadh Abdelkarim, Johanna H.M. Stroeve, Iuliana Popescu, Helene Duez, Vidya R. Velagapudi, Julie Dumont, Emmanuel Bouchaert, Theo H. van Dijk, Anthony Lucas, Emilie Dorchies, Mehdi Daoudi, Sophie Lestavel, Frank J. Gonzalez, Matej Oresic, Bertrand Cariou, Folkert Kuipers, Sandrine Caron, Bart Staels

Diabetes 2011;60(7):1861–1871

https://doi.org/10.2337/db11-0030

Published: 20 June 2011

View articletitled, Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity

Includes: Supplementary data

Update search

NARROW

Format

Journal

Article Type

Topics

Issue Section

Date

Availability

81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology

1223-P: Frequency and Predictors of Level 2 Time Above Range (TAR) in Older Adults with Type 2 Diabetes on Insulin Therapy—Data from the HYPOAGE Prospective Study

1624-P: Hudev-PRE, a Combination of Plant Extracts, Improves Glucose Homeostasis in Both High-Fat Diet C57Bl/6J and Ob/Ob Mice

1017-P: Association between Death at Day 28 and Components of Microvascular Disease of with Diabetes Hospitalized for Coronavirus Disease-2019 (COVID-19): The CORONADO Study

670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial

932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program

1103-P: Balancing the Risk of DKA and Severe Hypoglycemia with Sotagliflozin in Adults with Type 1 Diabetes

175-OR: Effect of Alirocumab in Individuals with Type 2 Diabetes and High Triglycerides and Low High-Density Lipoprotein Cholesterol

985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8

1212-P: Sotagliflozin Reduces Markers of Arterial Stiffness in T1D: Pooled Analysis from inTandem 1 and inTandem 2 Clinical Trials

1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA_1c Level at 52 Weeks in Adults with T1D

279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients

278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis

Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2)

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study)

The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency

Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only